Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271765 · ClinicalTrials.gov registry record · Phase 2
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
A Phase 2 study of Acute Myocardial Infarction, sponsored by Inotek Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 16
- Study locations
NCT00271765 is a Phase 2 study of Acute Myocardial Infarction that has completed, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 40 participants, below the 1,880-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (98% lower). The trial reports 16 study locations across 11 states.
The verdict
NCT00271765, a Phase 2 study of Acute Myocardial Infarction, has completed, sponsored by Inotek Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
Conditions Studied
Interventions
- DRUG INO-1001
Study Locations (16)
Other
- Rambam Medical Center - Haifa
- Meir Medical Center - Kfar Saba
- Hasharon Medical Center - Petah Tikva
- Rabin Medical Center - Petah Tikva
- - Rehovot
- Assaf Harofe Medical Centre - Ẕerifin
Florida
- Holy Cross Hospital - Fort Lauderdale
Indiana
- Porter Hospital - Valparaiso
Minnesota
- St. Paul Heart Clinic - Saint Paul
New Jersey
- - Newark
Ohio
- Toledo Hospital - Toledo
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
South Dakota
- Black Hills Cardiovascular Research - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00271765
The ClinicalTrials.gov registry entry for NCT00271765 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,880-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (98% lower). The listed sponsor is Inotek Pharmaceuticals Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which INO-1001 is the first listed.
NCT00271765 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT00271765 about?
NCT00271765 is a clinical study titled "A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention". The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
What is the current status of trial NCT00271765?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-01. Estimated completion is 2006-06.
What conditions does trial NCT00271765 study?
This clinical trial studies the following conditions: Acute Myocardial Infarction.
What interventions are being tested in trial NCT00271765?
The interventions under investigation include: INO-1001 (DRUG).
Who is sponsoring clinical trial NCT00271765?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00271765 being conducted?
This trial has 16 study locations across Florida, Indiana, Minnesota, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
COMPLETED · Phase 2
-
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
COMPLETED · Phase 2
-
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
RECRUITING · NA
-
Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock
RECRUITING
-
Abbott Vascular Medical Device Registry
RECRUITING
-
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.